STM JOURNALS

Emerging Trends in
Personalized Medicines

ISSN: 3049-1347
Volume 3, Issue 1, 2026
January–June
DOI (Journal): 10.37591/ETPM

https://journals.stmjournals.com/etpm

Review ETPM

A Review on the Interconnection Between Drug Design and Controlled Drug Delivery Systems

Mohd. Wasiullah[1], Piyush Yadav[2,*], Amit Pal[3]

Abstract

Drug discovery and delivery are two branches of science that have historically developed as independent areas of discovery – one focused on optimizing the properties of molecules for biological activity, and the other on controlling the rate, site, and duration for drug release. However, in contemporary pharmacy, these two areas have merged into a single integrated approach – where drug discovery and delivery strategies co-influence each other at each point of the development process. Rational drug design now considers pharmacokinetic and pharmacodynamic aspects dictated by delivery platforms, while sophisticated controlled drug delivery systems (CDDS) are developed with molecular characteristics in mind, with the goal of optimizing drug action. The purpose of this review is to highlight the relationship between drug design and CDDS, including the main principles and innovations that span the technology, molecular modeling, nanotechnology, and translational aspects that have accompanied the drug design and CDDS relationship. A primary focus is on how the relationship drug design, and CDDS advances toward more precision therapeutics, lowers systemic toxicity, and improves patient compliance. Finally, the state-of-the-art is assessed in terms of the practicality of computational design, more personalized delivery, and adaptive materials toward the drug design and delivery industries as a means of drug innovation.

Keywords: ADMET, artificial intelligence, controlled drug delivery, drug design, molecular modeling, nanotechnology

INTRODUCTION

Drug discovery and development have undergone revolutionary changes over the last few decades. What started as drug discovery through empirical methods mostly based on trial-and-error screening has evolved into more rational drug design processes increasingly governed by molecular biology, bioinformatics, and computational chemistry. Similarly, the field of pharmaceutics has progressed to more advanced controlled delivery approaches to varying spatiotemporal occurrence of drug release. Originally drug design was concerned with maximizing pharmacological activity without regard to physicochemical parameters, such as solubility, permeability, and stability, that are important for formulation development. Formulation scientists were left to deal with limitations of the drug post hoc through modification of the excipients or delivery route. It has now become more apparent that drug discovery and drug formulation are interrelated issues. The therapeutic performance of a drug is a function of the drug's next being delivered or released at the site of action, then the molecular affinity of the drug towards the biological target [1].

The intersection of drug design and delivery is a critical feature of pharmaceutical science today. This holistic approach allows for the design of drugs

***Author for Correspondence**
Piyush Yadav
E-mail: piyush61184@gmail.com

[1]Principal, Department of Pharmacy, Prasad Institute of Technology, Jaunpur, Uttar Pradesh, India
[2]Head, Department of Pharma: Chemistry, Prasad Institute of Technology, Jaunpur, Uttar Pradesh, India
[3]Scholar, Department of Pharmacy, Prasad institute of Technology, Jaunpur, Uttar Pradesh, India

Received Date: December 23, 2025
Accepted Date: January 22, 2026
Published Date: January 31, 2026

Citation: Mohd. Wasiullah, Piyush Yadav, Amit Pal. A Review on the Interconnection Between Drug Design and Controlled Drug Delivery Systems. Emerging Trends in Personalized Medicines. 2026; 3(1): 47–52p.

that are "designed-for-delivery," meaning that the molecular properties, such as lipophilicity, ionization, and metabolic stability, can be adjusted to be compatible with delivery technologies including liposomes, nanoparticles, polymer-based systems, and even implantable delivery systems.

This review aims to address the mechanistic, technological, and conceptual links between drug design and drug delivery systems, to establish holistic knowledge as to how they determine clinical success throughout two systems [2].

PRINCIPLES OF DRUG DESIGN

Rational Drug Design

Rational drug design (RDD) is the process of designing molecules purposefully based on our knowledge of biological targets and their corresponding molecular mechanisms. This method builds on the structural and functional characterization of a target, often performing X-ray crystallography, NMR spectroscopy, or cryo-electron microscopy. For instance, both structure-based drug design (SBDD) and ligand-based drug design (LBDD), take into consideration binding affinity, selectivity, and activity in the formation of a molecule library [3].

Physicochemical Properties and ADMET

ADMET (absorption, distribution, metabolism, excretion, and toxicity) properties define a drug's in vivo efficacy. There are multiple parameters that influence ADMET properties, most notably, molecular weight, log P (lipophilicity), hydrogen bond potential, and polar surface area. Lipinski's "Rule of Five" remains one of key precepts for aiding in the balance of "drug-likeness". Importantly, these parameters also dramatically influence the feasibility of formulation and alignment with the desired route of delivery.

Prodrug Design and Targeting

Prodrug approaches may be used to address barriers to delivery such as poor solubility or low permeability. Inactive precursors can be designed to convert to active drugs by modifying functional groups, participating in a close linkage between molecular design and delivery concerns – chemical modification serves as a design-level solution for delivery problems.

In-Silico and AI-Assisted Design

Recent advances in molecular docking, quantitative structure–activity relationship (QSAR) modeling, and machine learning have facilitated predictive optimization of drug candidates. Artificial intelligence (AI) algorithms can also integrate pharmacokinetic modeling, allowing for early prediction of delivery characteristics and formulation suitability, effectively shortening development timelines and improved economic viability [4, 5].

CONTROLLED DRUG DELIVERY (CDDS)

Concept and Classification

Controlled drug delivery systems are designed to release therapeutic agents at specified rates, time frames, and target sites. The main goal of controlled drug delivery is to maintain drug concentration at therapeutic levels and to continually minimize the "peaks and troughs" of drug delivery normally observed with standard dosage forms.

Three main classes of controlled drug delivery systems are:

- *Rate-Controlled Systems:* For example, matrix systems, reservoir systems.
- *Activation-Modulated Response Systems:* Activated by drug delivery due to physicochemical stimuli (pH, temperature, ultrasound, etc.) or external stimuli (e.g., light).
- *Feedback-Regulated Drug Delivery:* Medications can be delivered based upon biosensors or enzyme/modification of polymers to achieve modified feedback of medications.
- *Targeted Drug Delivery Systems:* For example, liposomes, nanoparticles, and antibody–drug conjugates [6, 7].

Benefits

CDDS improve bioavailability, minimize dosing frequency, increase patient adherence, and minimize adverse events in doses. They are particularly valuable for potent medications with narrow therapeutic indices or poor solubility.

Materials and Design Considerations

Polymers (natural and synthetic), lipids, and biodegradable matrices are utilized as the building blocks of delivery systems. The kinetics of drug release will depend on molecular interaction between drug and excipients. To develop a compatible delivery system, it is advantageous to have a deep understanding of physicochemical properties of the drug (solubility, crystallinity, partition coefficient).

Mechanistic Models of Release

Mechanisms of drug release include diffusion, dissolution, swelling, and erosion. using mathematical models, such as Higuchi, Korsmeyer–Peppas, and zero-order, can provide quantitative data about the dynamics of release. Release data should correspond to the pharmacokinetics of the drug as determined at the design phase [8].

INTERRELATIONSHIP BETWEEN DRUG DESIGN AND CONTROLLED DELIVERY

Design-for-Delivery Paradigm

Modern drug design typically takes formulation-relevant parameters into account in its early stages. For instance, if we are designing hydrophilic drugs for encapsulation into hydrophobic matrices, a chemical derivatization (to a hydrophobic derivative) may be part of the design phase, for example when the polymerization of hydrophilic molecules into an ultra-hydrophobic matrix is planned. Similarly, poorly soluble drugs may also include amorphous areas designed to favorably interact with nanoparticles for dispersion [9, 10].

Molecular Structure Factors Impacting Delivery

The chemical structure also determines compatibility with carriers, encapsulation efficiency, and release kinetics after delivery. For example, drugs with a high molecular weight or a high polarity will fail to permeate membranes, and therefore, the design process may include either molecular simplification or esterification to improve diffusion.

Delivery Characteristics Impacting Molecular Design

Similarly, delivery technologies can alter the path of molecular design. If the delivery technology selected is a polymeric implant, drug stability at physiological pH and temperature (or other relevant physical parameters) in some part of the design criteria. In fact, the constraints of delivery parameters whether deliberate or unintended will shape the design choices made, thereby promoting a bidirectional feedback loop between design and delivery [11].

Pharmacokinetic Synchronization

The effectiveness of treatment relies upon the synchronization between release kinetics and pharmacodynamics. The convergence of computational PK/PD modeling with molecular design will allow one to engineer the drug to achieve steady state concentrations in conjunction with delivery systems.

COMPUTATIONAL, MOLECULAR, AND NANOTECHNOLOGICAL INTEGRATION

Molecular Modeling for Optimizing Delivery

Sophisticated molecular dynamics simulations have been developed to analyze drug-polymer interactions to forecast encapsulation behavior, rate of diffusion, or degradation pathways. This information enables synthetic chemists to modify molecular structures for optimal compatibility with delivery carriers.

Nanotechnology Driven Delivery

Nanocarriers, such as liposomes, dendrimers, micelles, solid lipid nanoparticles, and polymeric nanoparticles, are a cutting edge (delivery science). When designing drugs with delivery systems, the

compatibility of the nanocarrier must be addressed, as it will require balance between charge, surface hydrophobicity, and steric stabilization [12, 13].

Smart and Stimuli-Responsive Systems

The design strategies continue to move toward combined mechanisms, utilizing several stimuli-responsive mechanisms, corresponding to pathophysiological stimuli such as pH-sensitive linkers or polymer transitions based on temperature stimulus. The molecular design will need to incorporate functionality-responsive design to provide a level of control for release.

Systems Biology and Network Pharmacology

Systems biology offers many opportunities for population-based multi-target drug development that aligns with their multi-functional drug delivery systems. Network pharmacology provides a holistic approach to drug-gene-pathway relationships, designed to enable informed and pathway-specific delivery vector selection.

CHALLENGES AND BARRIERS TO PRACTICE

Despite substantial advancements toward integrating design and delivery science into practice, numerous obstacles remain.

Predictive Limitations

Current computational models rarely account for the complexities of biological environments. There remains a limited ability to predict in vivo artist distribution and even less for in vivo release and biodistribution, resulting in differences between preclinical versus clinical applications.

Stability/Shelf Life/Manufacturability Constraints

Drugs designed for delivery systems may be optimized for delivery but may be unstable during processing and storage. Scale-up of nano and micro-structured formulations requires stability studies while maintaining strict control of critical design parameters such as particle size, polydispersity, and drug loading efficiency [14].

Regulation and Safety

The combination of new molecular drug entities and advanced drug delivery systems raise the level of complexity beyond the original drug-specific evaluation. Evaluating the safety profile for hybrid drug entity's containing new molecular drug entities and advanced drug delivery systems will require the added complexity of evaluation of both the new molecular drug entity(s) and the corresponding novel drug delivery system(s) safety profile for cellular and material toxicity [15–17].

Economic and Developmental Burdens

The integration of design and delivery will likely elevate early-phase research and development costs due to complex modeling, multi-disciplinary engagement, and sophisticated analytics, although these costs will be recuperated in improved clinical trial success rates.

FUTURE PROSPECTS

AI and In-Silico

AI-enabled models will both enhance and fundamentally change the coupling of design and delivery by modeling biological activity, as well as delivery performance. The structural suggestions from generative AI models will simultaneously optimize doses and affinity for the receptor.

Personalized and Adaptive Delivery

Profiling by genomics and pharmacogenomics is paving the way towards personalized medicines. Controlled delivery systems functioning within individual patients absolutely relying on a biomarker for that patient like glucose or enzymatic activity will require drugs that are designed to respond to that trigger [18–20].

Bioprinting and Smart Polymers

3D bioprinting will use molecularly designed drugs that will be used in patient-specific implants and dosage forms. Smart polymers will have integrated molecular triggers and dynamic covalent bonds or shape-memory or some other memory function for targeted, on-demand release.

Green Chemistry and Sustainable Design

The objective of a sustainable approach to drug design is to lessen the impact on the environment using biodegradable excipients and green synthetic pathways. The integration of eco-pharmaceutical design with delivery technologies will be the foundation for future ethical pharmaceutics [21–28].

CONCLUSION

The relationship between drug design and controlled drug delivery is a considerable advancement in pharmaceutical science. Molecular discovery and formulation development can no longer function as independent domains, and an integrative strategy is to develop therapeutics that embrace molecular engineering, delivery optimization, both experimental and computational modeling, and translational pharmacology. Success in integration is apparent in modern nanomedicines, antibody–drug conjugates, and gene delivery platforms, where both intelligent design and precise delivery are judged to be fine. The evolution of computational power along with artificial intelligence technologies and materials sciences will continue to blur the lines between designing a therapeutic molecule and the design of its delivery. This relationship opens a new era of developing safer, smarter, and more effective medicines.

REFERENCES

1. Langer R. Drug delivery and targeting. Nature. 1998;392(Suppl 6679):5–10. doi: 10.1038/32113.
2. Lipinski CA, Lombardo F, Dominy BW, Feeney PJ. Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings: The rule of five. Adv Drug Deliv Rev. 2001;46(1–3):3–26. doi: 10.1016/S0169-409X(00)00129-0.
3. Siepmann J, Peppas NA. Modeling of drug release from delivery systems based on hydroxypropyl methylcellulose (HPMC). Adv Drug Deliv Rev. 2001;48(2–3):139–157. doi: 10.1016/S0169-409X(01)00112-0.
4. Allen TM, Cullis PR. Drug delivery systems: Entering the mainstream. Science. 2004;303(5665):1818–1822. doi: 10.1126/science.1095833.
5. Langer R, Peppas NA. Advances in biomaterials, drug delivery, and bionanotechnology. AIChE J. 2003;49(12):2990–3006. doi: 10.1002/aic.690491202.
6. Batool M, Ahmad B, Choi S. A structure-based drug discovery paradigm. Int J Mol Sci. 2019;20(6):1383. doi: 10.3390/ijms20061383.
7. Ferreira LG, dos Santos RN, Oliva G, Andricopulo AD. Molecular docking and structure-based drug design strategies. Molecules. 2015;20(7):13384–13421. doi: 10.3390/molecules200713384.
8. Mitchell MJ, Billingsley MM, Haley RM, Wechsler ME, Peppas NA, Langer R. Engineering precision nanoparticles for drug delivery. Nat Rev Drug Discov. 2021;20(2):101–124. doi: 10.1038/s41573-020-0090-8.
9. Patra JK, Das G, Fraceto LF, Campos EVR, Rodriguez-Torres MP, Acosta-Torres LS, et al. Nano-based drug delivery systems: Recent developments and future prospects. J Nanobiotechnology. 2018;16(1):71. doi: 10.1186/s12951-018-0392-8.
10. Torchilin VP. Multifunctional, stimuli-sensitive nanoparticulate systems for drug delivery. Nat Rev Drug Discov. 2014;13(11):813–827. doi: 10.1038/nrd4333.
11. Zhang Y, Chan HF, Leong KW. Advanced materials and processing for drug delivery: The interface of design and delivery. Adv Drug Deliv Rev. 2013;65(5):791–792. doi: 10.1016/j.addr.2013.03.001.
12. Dutta D, et al. Integration of artificial intelligence in drug discovery and development: Trends and perspectives. Trends Pharmacol Sci. 2023;44(7):566–580. doi: 10.1016/j.tips.2023.04.004.
13. Patra PA, et al. Nanomedicine: Past, present, and future—A global perspective. J Control Release. 2015;205:1–13. doi: 10.1016/j.jconrel.2015.02.039.
14. Yusuf A, et al. Nanoparticles as drug delivery systems: A review of the state-of-the-art and future directions. Polymers (Basel). 2023;15(7):1596. doi: 10.3390/polym15071596.

15. Siepmann J, Goepferich A. Mathematical modeling of bioerodible, polymeric drug delivery systems. Adv Drug Deliv Rev. 2001;48(2–3):229–247. doi: 10.1016/S0169-409X(01)00116-8.
16. Korsmeyer RW, Gurny R, Doelker E, Buri P, Peppas NA. Mechanisms of solute release from porous hydrophilic polymers. Int J Pharm. 1983;15(1):25–35. doi: 10.1016/0378-5173(83)90064-9.
17. Vlieghe P, Khrestchatisky M. Prodrug approach in modern drug design: Strategies and examples. Med Res Rev. 2013;33(2):1–28. doi: 10.1002/med.21245.
18. Abet V, et al. Prodrug approach: An overview of recent cases (2004–2016). Eur J Med Chem. 2017;127:810–827. doi: 10.1016/j.ejmech.2016.10.061.
19. Najjar A, et al. The prodrug approach in the era of drug design. Drug Des Devel Ther. 2019;13:1–18. doi: 10.2147/DDDT.S176450.
20. N'Da DD. Prodrug strategies for enhancing percutaneous and transdermal delivery. Molecules. 2014;19(12):20780–20816. doi: 10.3390/molecules191220780.
21. Tiwari G, Tiwari R, Sriwastawa B, Bhati L, Pandey S, Pandey P, et al. Drug delivery systems: An updated review. Pharmaceutics. 2012;4(1):1–19. doi: 10.3390/pharmaceutics4010001.
22. Zhang R, et al. Smart polymers for controlled release: Progress and prospects. Prog Polym Sci. 2021;116:101386. doi: 10.1016/j.progpolymsci.2021.101386.
23. Jahangirian H, et al. A review of drug delivery systems based on nanotechnology and green chemistry. Int J Nanomedicine. 2017;12:5577–5593. doi: 10.2147/IJN.S132838.
24. Fang J, Nakamura H, Maeda H. The EPR effect: Unique features of tumor blood vessels for drug delivery. Adv Drug Deliv Rev. 2011;63(3):136–151. doi: 10.1016/j.addr.2010.04.009.
25. Kakkar A, et al. Designing nanomedicines for clinical translation. Nat Rev Chem. 2022;6(8):566–581. doi: 10.1038/s41570-022-00401-9.
26. Doxsee CL, et al. Antibody–drug conjugates: Design, development, and delivery considerations. Nat Rev Drug Discov. 2020;19(11):763–780. doi: 10.1038/s41573-020-00043-3.
27. Boiani M, González M. Imidazole and benzimidazole derivatives: Chemotherapeutic design considerations. Mini Rev Med Chem. 2005;5(4):409–424. doi: 10.2174/1389557053765513.
28. Mitchell MJ, et al. Engineering nanoparticles for precision medicine and overcoming drug delivery barriers. Nat Rev Drug Discov. 2021;20(2):101–124. doi: 10.1038/s41573-020-0090-8.

